Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021279 · ClinicalTrials.gov registry record · NA
ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 161
- Enrollment target
NCT02021279 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 161 participants.
The verdict
NCT02021279, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 161 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.
Interventions
- DEVICE MatriStem Pelvic Floor Matrix
- PROCEDURE native tissue repair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2021-04-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021279
The ClinicalTrials.gov registry entry for NCT02021279 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MatriStem Pelvic Floor Matrix is the first listed.
NCT02021279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02021279 about?
NCT02021279 is a clinical study titled "ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study". The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.
What is the current status of trial NCT02021279?
This trial is currently completed. It is a NA study. The enrollment target is 161 participants. The study started on 2014-06-11. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT02021279?
The interventions under investigation include: MatriStem Pelvic Floor Matrix (DEVICE), native tissue repair (PROCEDURE).
Who is sponsoring clinical trial NCT02021279?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.